Table 2.
Grade 3/4 toxicity profile of induction chemotherapy
| Parameter | Pre-RT chemotherapy |
Post-RT chemotherapy |
Total (62 cycles) | ||
|---|---|---|---|---|---|
| CECV (18 cycles) | CEIV (17 cycles) | CECV (14 cycles) | CEIV (13 cycles) | ||
| Hematologic toxicity | |||||
| Chemotherapy dose (%)a) | 99.6 (79.5-104.5) | 100 (79.1-102.8) | 74.5 (70.4-76.7) | 73.6 (69.5-76.5) | - |
| Dose reduction > 5% | 1 (5.6) | 1 (5.9) | 0 | 1 (7.7) | 3 (4.8) |
| Interval to next cycle (day) | 29 (24-58) | 32 (25-37) | 28 (26-39) | 32 (27-38) | 29 (24-58) |
| Interval > 35 days | 2 (11.1) | 1 (5.9) | 1 (7.1) | 4 (30.8) | 8 (12.9) |
| Delayed hematologic recovery | 0 | 1 (5.9) | 1 (7.1) | 2 (15.4) | 4 (6.5) |
| Other causes | 2 (11.1)b) | 0 | 0 | 2 (15.4)c) | 4 (6.5) |
| Duration of neutropenia (day) | 8 (4-11) | 8 (4-20) | 8 (5-15) | 6 (1-12) | 7.5 (1-20) |
| No. of platelet transfusions | 4 (1-10) | 3 (0-14) | 2 (1-8) | 3 (1-8) | 3 (0-14) |
| Neutropenic fever | 12 (66.7) | 8 (47.1) | 9 (64.3) | 7 (53.8) | 36 (58.1) |
| Positive blood culture | 1 (5.6) | 2 (11.8) | 0 | 1 (7.7) | 4 (6.5) |
| Non-hematologic toxicity | |||||
| Elevation of liver enzymes | 1 (5.6) | 1 (5.9) | 0 | 0 | 2 (3.2) |
| Hyperbilirubinemia | 0 | 0 | 0 | 0 | 0 |
| Renal insufficiency | 0 | 0 | 0 | 0 | 0 |
| Hypokalemia | 2 (11.1) | 2 (11.8) | 0 | 1 (7.7) | 5 (8.1) |
| Hyponatremia | 1 (5.6) | 0 | 0 | 0 | 1 (1.6) |
Values are presented as median (range) or number (%). CECV, cisplatin+etoposide+cyclophosphamide+vincristine; CEIV, carboplatin+etoposide+ifosfamide+vincristine.
a)
Percent of calculated dose,
b)
Delay due to shunt problems,
c)
Delay due to high-dose chemotherapy scheduling.